Repository logo
 
Publication

Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer

2023-10Journal article Open access
Simple item page
dc.contributor.authorBarreto, Inês
dc.contributor.authorFigueiredo, Sara
dc.contributor.authorTonin, Fernanda
dc.contributor.authorVilariça, Ana Sofia
dc.contributor.authorHasmucrai, Direndra
dc.contributor.authorAlves, Paula
dc.date.accessioned2024-04-02T11:28:00Z
dc.date.available2024-04-02T11:28:00Z
dc.date.issued2023-10
dc.description.abstractOsimertinib, a third-generation tyrosine kinase inhibitor (TKI), was recently introduced in several countries, including Portugal (reimbursement in 2021), as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating proto-oncogene epidermal growth factor receptor mutations (EGFRm), after showing significant efficacy and safety when used in patients with EGFR-T790M resistance mutations. However, despite advances in personalized target treatments in this field, challenges regarding patients’ journey (e.g., therapy selection criteria, EGFR-TKI optimal sequencing, treatment beyond second-line) still exist.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBarreto I, Figueiredo S, Tonin FS, Vilariça AS, Hasmucrai D, Alves P. Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer. Port J Card Thorac Vasc Surg. 2023;30(3):9-11.pt_PT
dc.identifier.doi10.48729/pjctvs.381pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/17243
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSociedade Portuguesa de Cirurgia Cárdio-Torácica e Vascularpt_PT
dc.relation.publisherversionhttps://pjctvs.com/index.php/journal/article/view/381pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectLung cancerpt_PT
dc.subjectNon-small-cell lung cancerpt_PT
dc.subjectEGFR mutationpt_PT
dc.subjectReal-world datapt_PT
dc.subjectTyrosine kinase inhibitorspt_PT
dc.titleReal-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage11pt_PT
oaire.citation.issue3pt_PT
oaire.citation.startPage9pt_PT
oaire.citation.titlePortuguese Journal of Cardiac Thoracic and Vascular Surgerypt_PT
oaire.citation.volume30pt_PT
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancer.pdf
Size:
410.88 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos